Insight into recent reforms and initiatives in Austria: implications for key stakeholders

References

• Hofmarcher M, Rack H-M. Austria: health system review. Health Syst. Trans.8(3), 1–247 (2006).
   Google Scholar
• Sturm H, Austvoll-Dahlgren A, Aaserud M et al. Pharmaceutical policies: effects of financial incentives for prescribers (review). Cochrane Database Syst. Rev.3, CD006731 (2007).
   Google Scholar
• Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. Br. Med. J.317, 465–468 (1988).
   Google Scholar
• Barber N, Bradley C, Barry C et al. Measuring the appropriateness of prescribing in primary care: are current measures complete? J. Clin. Pharm. Ther.30, 533–539 (2005).
   PubMed Web of Science ®Google Scholar
• Führlinger S. Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria. Wien. Med. Wochenschr.156, 612–618 (2006).
   PubMedGoogle Scholar
• Barry M, Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev. Pharmacoeconomics Outcome Res.7(6), 605–611 (2007).
   PubMedGoogle Scholar
• Walter E, Zehetmayr S. Guidelines for health-economic evaluations in Austria. Wien. Med. Wochenschr.156, 628–632 (2006).
   PubMedGoogle Scholar
• Grandfils N, Sermet C. Pharmaceutical policy in France: a mosaic of reforms. Eurohealth12(3), 15–17 (2006).
   Google Scholar
• Allenet B, Barry H. Opinion and behaviour of pharmacists towards the substitution of brand products by generic drugs: survey of 1000 French community pharmacists. Pharm. World Sci.25(5), 197–202 (2003).
   PubMedGoogle Scholar
• Andersson K, Sonesson C, Petzold M et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf.14, 341–348 (2005).
   PubMed Web of Science ®Google Scholar
• Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26(2), 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Hauptverband der Österreichischen Sozialversicherungsträger. Erstattungskodex – EKO. Gültig ab 1. Jänner 2007.
   Google Scholar
• Auterith A. Initiative Arznei & Vernunft - Evaluierung der Therapieempfehlung “Asthma/COPD”. Juni 2002 Institut für Medizinische Statistik ([email protected]).
   Google Scholar
• Wettermark B, Hammar N, Fored M et al. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf.16, 726–735 (2007).
   PubMed Web of Science ®Google Scholar
• Wolzt M, Ohrenberger G, Reichardt B. Cost reduction with project based prescription of generic ACE inhibitors. Wien. Klin. Wochenschr.115 (1–2), 23–28 (2003).
   PubMedGoogle Scholar
• Gouya G, Reichardt B, Bidner A, Weissenfels R, Wolzt M. Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurances and patients. Wien. Klin. Wochenschr.120, 89–95 (2008).
   PubMedGoogle Scholar
• Atella V, Schafheutle E, Noyce P, Hassell K. Affordability of medicines and patients’ cost-reducing behaviour – empirical evidence based on SUR estimates from Italy and UK. Appl. Health Econ. Health Policy4(1), 23–35 (2005).
   PubMedGoogle Scholar
• Jack A. Balancing Big Pharma’s books. Br. Med. J.336, 418–419 (2008).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Andersson K, Gustafsson L, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26(27), 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Garattini L, Ghislandi S. Off-patent drugs in Italy: a short sighted view? Eur. J. Health Econ.7, 79–83 (2006).
   PubMedGoogle Scholar
• Paris V. Pharmaceutical regulation in France 1980 – 2003. Int. J. Health Plann. Manage.20, 307–328 (2005).
   PubMed Web of Science ®Google Scholar
• Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy82, 330–339 (2007).
   PubMed Web of Science ®Google Scholar
• Wells J, Cheong-Leen C. NICE appraisals should be everyone’s business. Br. Med. J.334, 936–938 (2007).
   PubMedGoogle Scholar
• Barrett A, Roques T, Small M, Smith R. How much will herceptin really cost? Br. Med. J.333, 1118–1120 (2006).
   PubMed Web of Science ®Google Scholar
• Motola D, De Ponti F, Rossi P, Martini N, Montanaro N. Therapeutic innovation in the EU: analysis of the drugs approved by the EMEA between 1995 and 2003. Br. J. Clin. Pharmacol.59, 475–478 (2004).
   Web of Science ®Google Scholar
• Motola D, De Ponti F, Poluzzi E et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol.62, 610–616 (2006).
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele V. How can we regulate medicines better. Br. Med. J.335, 803–805 (2007).
   PubMedGoogle Scholar
• Kastelein J, Akdim F, Stroes E, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med.358, 1431–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Lapostolle F, Catineau J, Lapandry C, Adnet F. Endpoints in studies on myocardial infarction. Lancet369, 1430 (2007).
   PubMedGoogle Scholar
• Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. Br. Med. J.326, 1171–1173 (2003).
   PubMed Web of Science ®Google Scholar
• Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson B. Initial severity and antidepressant benefits: a meta analysis of data submitted to the Food and Drug Administration. PLoS Med.5(2), E45 (2007).
   Google Scholar
• Duerden M, Miller J, Godman B, Mallinson M, Sullivan N. Centralised guidance – how NICE and SIGN impact on care in the UK. Bausteine fur ein neues Gesundheitswesen – Technik, Ethik, ¨Okonomie” Klusen N, Straub E (Eds.). Nomos Verlagsgesellschaft, Baden-Baden (No. 6 of the series ” Beitrage zum Gesundheitsmanagement” by Nobert Klusen and Andreas Meusch) (2003).
   Google Scholar
• Schneider A, Wensing M, Biessecker K et al. Impact of quality circles for improvement of asthma care: results of a randomized controlled trial. J. Eval. Clin. Pract.14, 185–190 (2008).
   PubMed Web of Science ®Google Scholar
• Rochaix L, Wilsford D. State autonomy, policy paralysis: paradoxes of institutions and culture in the French health care system. J. Health Polit. Policy Law30(1–2), 97–119 (2005).
   PubMed Web of Science ®Google Scholar
• Krammer H. Pharmacoeconomic analyses – chance or 4th hurdle for innovative drugs. Wien. Med. Wochenschr.156, 606–611 (2006).
   PubMedGoogle Scholar
• IMAS International. Initiative Arznei & Vernunft – Ergebnisse einer repräsentativen Resonanzstudie under Ärzten. June 2003. Archiv-Nr.:7074.
   Google Scholar